| Literature DB >> 34951957 |
Hannah N Bell1, Ryan J Rebernick2, Joshua Goyert1, Rashi Singhal1, Miljan Kuljanin3, Samuel A Kerk1, Wesley Huang1, Nupur K Das1, Anthony Andren1, Sumeet Solanki1, Shannon L Miller4, Peter K Todd5, Eric R Fearon6, Costas A Lyssiotis7, Steven P Gygi8, Joseph D Mancias9, Yatrik M Shah10.
Abstract
Microbial dysbiosis is a colorectal cancer (CRC) hallmark and contributes to inflammation, tumor growth, and therapy response. Gut microbes signal via metabolites, but how the metabolites impact CRC is largely unknown. We interrogated fecal metabolites associated with mouse models of colon tumorigenesis with varying mutational load. We find that microbial metabolites from healthy mice or humans are growth-repressive, and this response is attenuated in mice and patients with CRC. Microbial profiling reveals that Lactobacillus reuteri and its metabolite, reuterin, are downregulated in mouse and human CRC. Reuterin alters redox balance, and reduces proliferation and survival in colon cancer cells. Reuterin induces selective protein oxidation and inhibits ribosomal biogenesis and protein translation. Exogenous Lactobacillus reuteri restricts colon tumor growth, increases tumor reactive oxygen species, and decreases protein translation in vivo. Our findings indicate that a healthy microbiome and specifically, Lactobacillus reuteri, is protective against CRC through microbial metabolite exchange.Entities:
Keywords: Lactobacillus reuteri; Microbiome; Reuterin; colorectal cancer; metabolites; protein oxidation
Mesh:
Substances:
Year: 2021 PMID: 34951957 PMCID: PMC8847337 DOI: 10.1016/j.ccell.2021.12.001
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 38.585